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A B S T R A C T
Background: While human papillomavirus (HPV) DNA testing oﬀers high sensitivity for the detection of sig-
niﬁcant cervical disease, its speciﬁcity is suboptimal given the high prevalence of transient HPV infections (CIN1
or less). Biomarkers to identify those suﬀering from low grade disease from those with high grade disease could
save healthcare costs and reduce patient anxiety.
Objective: The objective of the present work was to develop and test an immunohistochemistry (IHC)-based dual
viral and cellular biomarker strategy which was applicable to liquid based cytology (LBC) samples.
Study design: We developed a novel IHC assay for detection of HPV E4 and cellular minichromosome main-
tenance (MCM) proteins in routinely taken cervical LBC samples using cytospin-prepared slides. The assay was
applied to a prospective cohort of Scottish women referred to a colposcopy clinic due to preceding cytological
abnormalities. The performance of the biomarkers for detection of clinically insigniﬁcant (CIN1 or less) versus
signiﬁcant disease was determined.
Results: A total of 81 women were recruited representing 64 cases of<=CIN1 and 28 of CIN2+ . Biomarker
performance relative to histopathology outcomes showed high levels of MCM detection was signiﬁcantly asso-
ciated with CIN2+ (p=0.03) while E4 was detected more frequently in<=CIN1 (p=0.06).
Conclusions: Combined detection of a host proliferation marker and a marker of viral gene expression could
allow triage of cases of clinically insigniﬁcant disease prior to colposcopy. However, there was overlap between
distributions of MCM levels in CIN2+ and<=CIN1 suggesting that additional biomarkers would be required
for improved speciﬁcity. Combined with cytospin-prepared slides this approach could provide a means of risk
stratiﬁcation of disease in low resource settings.
1. Background
Clinically insigniﬁcant cervical disease represents transient,
asymptomatic HPV infections that are cleared by the immune system
[1]. Clinically signiﬁcant infections are not cleared/not detected by the
immune system leading to persistent infections that can progress to
cancer [2,3]. The high prevalence of clinically insigniﬁcant HPV in-
fections, particularly in young women, means the HPV DNA tests in
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clinical use can lack speciﬁcity because they detect presence or absence
of viral nucleic acid but cannot measure virus activity. Virus activity is
the expression of the virus genome and the impact this has on host
genome expression, and has potential to be a sensitive and speciﬁc
indication of cervical disease [4,5]. New diagnostic approaches to
identify transient versus signiﬁcant HPV infection would improve the
management of associated diseases immensely.
The infectious HPV life cycle is tightly linked to the diﬀerentiation
process of the host epithelium [3]. HPV infects actively dividing basal
epithelial cells and establishes its episomal genome at low copy number
in the nuclei of these cells. Infected basal cells can move out of the basal
layer as transit amplifying cells, which undergo keratinocyte terminal
diﬀerentiation. During this process, the virus displays a highly orche-
strated gene expression programme that responds to keratinocyte dif-
ferentiation. Viral E6 and E7 proteins stimulate progression of the cell
cycle from G1 into S-phase in order to allow replication of viral gen-
omes [5]. In the mid layers of the epithelium, increased synthesis of
HPV E1 and E2 proteins allows viral genome replication and HPV E4
protein, the most abundant viral protein, is synthesised and facilitates
viral replication and virion egress.
Most HPV infections are cleared by the immune system. However, if
an infection becomes persistent in the epithelium, the host and viral
genomes undergo alterations that make progression to preneoplastic
and neoplastic disease more likely. Key among these changes due to
persistence is increased expression of HPV E6 and E7 proteins leading
to increased levels of cell cycle proteins such as p16, Ki67 and MCM.
[3,6,7]. Therefore, increased viral E6 and E7 expression is a feature of
persistent, clinically signiﬁcant disease. However, these proteins are
hard to detect in < CIN3 due to low expression levels in non-persistent
(i.e. normal) HPV infections. Instead, surrogate biomarkers of E6/E7
activity are used. p16 is considered the best validated “gold standard”
for detecting increased HPV E6 and E7 activity in clinical samples [8,9]
but MCM, a cellular marker of DNA replication, is an alternative sur-
rogate biomarker [10–12]. Previous studies revealed that increased
MCM (as a surrogate for E7) was a potential biomarker of clinically
signiﬁcant disease [11,12]. In contrast, E4 is a potential biomarker of
clinically insigniﬁcant disease because in an analysis of formalin-ﬁxed
paraﬃn-embedded tissues, its expression levels were greatest in CIN1
and lowest in CIN3 [12], and there are excellent antibodies against E4
[13].
2. Objectives
Biomarker-based risk-stratiﬁcation of HPV infection is a key priority
for development given the increasing move to cervical screening pro-
grammes based on primary HPV testing. A single biomarker may be less
optimal for disease stratiﬁcation compared to a biomarker combina-
tion/matrix. A matrix which incorporates both a viral and a cellular
target may confer sensitivity and speciﬁcity respectively. Here, we de-
scribe an initial investigation into the performance of a dual biomarker
based on IHC-based detection of E4 and MCM in routinely taken liquid
based cytology (LBC) to determine/stratify underlying disease.
3. Study Design
3.1. Clinical samples
LBC samples were collected with informed consent from a cohort of
81 women referred to a colposcopy clinic in the west of Scotland. LBC
samples were allocated a study number in the clinic unrelated to any
patient identiﬁers, stored at 4 °C and transferred to the research la-
boratory.
3.2. Disease ascertainment
Disease was deﬁned by histopathology results: with signiﬁcant/high
grade deﬁned as histology-conﬁrmed CIN2+, insigniﬁcant/no disease
deﬁned as histology conﬁrmed<=CIN1 or no clinically indicated
biopsy due to no abnormality detected on colposcopy.
3.3. HPV genotyping
HPV genotyping was with the Optiplex HPV Genotyping Assay
(DiaMex, Heidelberg, Germany) according to manufacturer’s instruc-
tions. This PCR based test with luminex technology can resolve 24 HPV
types (HPV6, 11, 16, 18, 26, 31, 33, 35, 39, 42, 43, 44, 45, 51, 52, 53,
56, 58, 59, 66, 68, 70, 73, 82) including all HR-HPV types as deﬁned by
the International Agency on Cancer.
3.4. Cell culture
HeLa cells were grown in Dulbecco’s modiﬁed eagles medium
(Invitrogen), 10% foetal calf serum (Invitrogen) and penicillin (50 U/
ml)/ streptomycin (50 μg/ml) (Invitrogen), at 37 °C in a 5% CO2 hu-
midiﬁed incubator. Transfection with E4 expression plasmid pMV11
was with Lipofectamine 2000 according to the manufacturer’s instruc-
tions.
3.5. Cytospin and ThinPrep
LBC samples (100 μl) in PreservCyt Solution (Hologic) were de-
posited on Klinipath plus slides using a Shandon 3 Cytospin (450 rpm,
10min). Slides were ﬁxed for 10min in 10% buﬀered formalin and
washed twice in buﬀer TBS-T (10mM Tris−HCl, pH7.5, 10mM EDTA,
100mM NaCl + 1% (v/v) Tween-20). Thinprep slides were prepared
using the ThinPrep T2000 (Hologic) using 20ml LBC samples in
PreservCyt Solution (Hologic). Slides were brieﬂy placed in 95% (v/v)
ethanol and treated with Cytoﬁx (Cellpath), immersed in 50% (v/v)
ethanol for 10min and ﬁxed for 10min in 10% buﬀered formalin,
followed by washing in TBS-T.
3.6. Immunohistochemistry
Heat-induced epitope retrieval was carried out in 10mM sodium
citrate buﬀer, pH 6.0 using a Menarini Access Retrieval Unit, at 110⁰C
on full pressure for 10min. Slides were loaded on to a Dako
Autostainer, rinsed in TBS-T, blocked in Dako Real TM peroxidise-
blocking solution for 5min followed by washing in TBS-T. Slides were
incubated for 30min in primary antibodies diluted in Dako universal
diluent (1/800 for monoclonal antibody FH1.1 reactive against E4 from
HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 67, 70
(a gift from John Doorbar [13,14])) and 1/100 for MCM2 rabbit
polyclonal antibody (Abcam ab31159). Following two washes in TBS-T,
slides were incubated with secondary antibody for 30min (Dako
K4001and K4003), washed twice in TBS-T, incubated for 10min in
Dako K5007 DAB followed by three washes in water. Slides were
counterstained with Gills Haematoxylin, dehydrated, cleared and then
mounted in synthetic resin.
3.7. Optimisation of staining and acceptance criteria
At least 3 photographs of stained cells were taken across each slide.
Images were input into Photoshop. One individual determined total cell
numbers in each ﬁeld of view by counting haematoxylin-stained nuclei,
then MCM or E4 positive cells were counted by two diﬀerent in-
dividuals independently blind to the clinical data. Averages of the two
counts were taken for further analysis. Most samples contained intact
cells and some cell fragments. Cytobrush acquisition of samples can
damage cells. We counted staining of only intact cells because E4 is a
cytoplasmic stain while MCM is a nuclear stain and we wished to be
able to compare levels of E4 and MCM-stained cells in the sample co-
hort. Some LBC samples contained clumps of material that non-
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speciﬁcally trapped antibody. Therefore, samples were ﬁltered using a
cell strainer size 70 μm (Corning CLS431751 SIGM).
3.8. CINtec
Thinprep slides were stained using the Roche CINtec®Plus system on
the Roche Ultra immunohistochemistry platform (Roche MTM
Laboratories) from residual LBC material. CINtec PLUS interpretation
was blind to other results. Samples with one or more cervical epithelial
cells that simultaneously showed brown cytoplasmic immunostaining
(p16) and red nuclear immunostaining (Ki-67) were classiﬁed as posi-
tive regardless of the morphologic appearance of the cells. Slides with
excessive background staining were considered not evaluable and ex-
cluded from analysis.
3.9. Evaluation of clinical performance of MCM and E4
Basic descriptive statistics stratiﬁed by grade of disease were pro-
duced and the distribution of both MCM and E4 values were visualised
in boxplots. Diﬀerences in E4 and MCM levels by disease grade were
evaluated using logistic regression were the outcome variable was high-
grade vs low-grade/normal disease. Finally MCM and E4 were con-
sidered together by examining the correlation between the measures
and examining if this diﬀered by disease group. Both MCM and E4 were
considered together in a multivariable logistic regression model. This
approach was used to access the association between biomarker and
disease grade because the numbers in each disease grade were quite low
for splitting into training and test data sets for building and testing a
prediction model.
4. Results
The aim of the study was to determine the performance of E4, a
biomarker of transient HPV infection (≤CIN1), in combination with
MCM2, a biomarker of signiﬁcant cervical disease in a cohort of pa-
tients who had an abnormal Pap smear test result, were called to attend
a colposcopy clinic, and tested positive for HPV.
4.1. Conﬁrmation of analytical performance of MCM and E4 antibodies
To test speciﬁcity of the antibodies for cellular MCM and viral E4
proteins, HeLa cells, and HeLa cells transfected with an expression
plasmid for HPV16 E4 were suspended in PreservCyt, stained with E4
and MCM antibodies and visualised by immunoﬂuorescence micro-
scopy. Fig. 1A shows E4 detection throughout the HeLaE4 cells, but not
the untransfected HeLa cells, while nuclear MCM was detected in both
cell types as expected (Fig. 1B).
4.2. Testing E4 and MCM detection by IHC on ThinPrep versus cytospin
slides
We compared cytospin centrifugation to the ThinPrep method
(T2000) to determine the best slide preparation for IHC analysis using
an initial cohort of 20 LBC samples. The same antigen retrieval protocol
was used for each slide type. Cytospin performed better than Thinprep
because adherence of LBC cells on the ThinPrep-prepared slides was
poor following the antigen retrieval protocol required for eﬃcient im-
munostaining with the selected biomarkers. For cytospin-prepared
slides, only 100 μl of each LBC sample was required thus ensuring that
multiple biomarkers could be tested on a single sample. Finally, cy-
tospin deposits two cell populations on a single slide meaning that an
antibody-negative control could be included on each slide (Fig. 2A).
Cells were counted positive for E4 if the marker was detected in the
cytoplasm (Fig. 2E-G), and for MCM if staining was in the nucleus
(Fig. 2 B–D). Three images are shown for each biomarker stain to re-
present the range of staining obtained.
4.3. Description of clinical cohort and underlying pathology
81 patients referred to a colposcopy clinic in the West of Scotland as
a consequence of preceding cytological abnormalities were consented
to the study and an LBC sample was taken in the clinic from each pa-
tient for the study. The average age of the cohort was 31 years (range
20–60 years). HPV was detected in 78/81 (96.3%) samples with HR-
HPV detected in 66/81 (81.5%) samples (Supplementary Table 1). One
third of all study participants were infected with HR-HPV16 and/or 18
(27/81, 33.3%). Following histopathological examination, there were
18 cases of CIN2+, 40 cases of CIN1 and 22 were designated “normal”
or “nil” or “no biopsy”. All CIN2+, 38/40 CIN1 and all “normal” cases
were positive for HR-HPV. Only HR-HPV positive samples were in-
cluded in the analysis.
4.4. Overall MCM and E4 positivity in LBC samples
Of the 81 clinical samples, 73 and 71 respectively had suﬃcient
intact cells to allow MCM and E4 antibody staining. All 73 samples
examined were positive for MCM (90.1%). Of the 71 samples that had
suﬃcient cell numbers, 45 (63.4%) were positive for E4. The percen-
tage of cells within a sample positive for MCM ranged from 3 to 86.7%
with an average of 27.5%. MCM will normally be expressed in any cell
undergoing cell cycle, e.g. in epithelial stem cells or in cells during
wound closure. Therefore, there may always be some MCM expression
in cervical tissue so we decided not to count as positive any sample with
any MCM detection. An arbitrary limit of> 20% of cells stained within
a cell population was chosen as “high” (or positive) MCM because this
was just below the average value and on the upward shoulder of a
normal distribution plot of MCM values (Supplementary Fig. 1). The
range of cells in any sample positive for E4 was 0 to 80.6% with an
average of 5.5%. E4 staining appeared to fall into two classes, no, or
very few cells stained (43 samples), or> 5% (28 samples) of cells
stained. For these two reasons samples were designated “high” E4 if
staining was detected in ≥ 5% of cells.
4.5. Does biomarker matrix detection correlate with histological disease
status?
69 samples analysed were positive for HR-HPV that could be de-
tected with the pan-E4 antibody. There was a segregation of E4 and
MCM staining in our clinical cohort: 70.9% of samples had either high
MCM/lowE4 (58.2%) or high E4/lowMCM (12.7%) staining. Of the
remainder, 7.3% had high E4/high MCM and 21.8 had low E4/low
MCM (Fig. 3). MCM positivity (> 20% of cells stained) was statistically
more likely to be present in CIN2+ (p=0.03). Conversely, E4 detec-
tion (≥ 5%) was more frequent in CIN1 and normal/nil/no biopsy but
just failed to reach statistical signiﬁcance (p=0.06). MCM marked
LBCs graded CIN2+ when compared with low grade/normal combined
(Fig. 4A), or low grade or normal separately (Fig. 4B). E4 levels were
very similar in combined low grade/normal samples compared with
CIN2+ (Fig. 4C) but were greater in samples graded as histologically
normal (but HPV-positive) compared to low grade or CIN2+ (Fig. 4D).
p-values were calculated for MCM and E4 detection considering CIN2+
versus CIN1 and CIN2+ versus normal and are shown on the graphs
(Fig. 4C, D). None were less than or equal to p=0.05 due to the small
numbers in each group.
4.6. Comparison of MCM detection in cytospin-prepared slides with p16
detection using CINtec
The ability of MCM detection in cytospin-prepared slides to identify
signiﬁcant disease was compared to the detection of p16/Ki67 using
CINtec. Of the 73 MCM-positive samples, 12 were excluded from ana-
lysis due to either insuﬃcient cells or unsatisfactory results. Sensitivity
was 1.00 while speciﬁcity was 0.404. Data from the remaining 61 LBCs
A. Stevenson et al. Journal of Clinical Virology 108 (2018) 19–25
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Fig. 1. Validation of E4 and MCM antibody
staining in cytospin cell preparations. A.
HeLa cells or B. HeLa cells transfected with an
expression plasmid for HPV16 E4 were grown
and harvested in PreservCyt. cell populations
were deposited on slides by cytospin, stained
with antibodies against MCM or E4 and visua-
lised using immunoﬂuorescence microscopy.
Fig. 2. Criteria for staining positivity on
LBC cells. A. –ve, negative control staining. B-
DMCM2 staining showing brown-stained nu-
clei (black arrowheads). Unstained nuclei are
blue due to the hematoxylin counterstain (gray
arrowheads). B. a typical ﬁeld of view from the
sample cohort showing several MCM-stained
nuclei. C. Many packed cells showing varia-
bility in strength of MCM staining. D. Some
samples contained debris which trapped anti-
body. However, clear positive brown-stained
nuclei and negative blue-stained nuclei were
visible. The arrow in B. indicates a nucleus
with partial cytoplasm. To ensure that only
intact cells were counted, such cells were ex-
cluded from the counts. E–G, E4 staining
showing brown-stained cytoplasm (black ar-
rowheads). Unstained cells are shown with
blue nuclei due to the hematoxylin counter-
stain (gray arrowheads). E. a typical ﬁeld of
view from the sample cohort showing one E4
stained cell. F. E4 staining was stronger in
some samples. G. E4 staining was sometimes
seen in only a portion of the cytoplasm and is
likely due to how cells were deposited on the
cytospin slides.
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showed an accuracy of 0.639 comparing cytospin MCM detection with
CINTec positivity. MCM detection showed a sensitivity of 0.651 and a
speciﬁcity of 0.611 at detecting high grade disease.
5. Discussion
Since its introduction, cervical screening via cytology has reduced
incidence of cervical cancer [15]. However, cytology is inherently
subjective with variable performance across settings. Molecular HPV
testing is becoming the optimal method of primary cervical screening
[16] and has been used, successfully as a “test of cure” of treatment
[17]. While the sensitivity, negative predictive value and objectivity of
molecular HPV tests are good, they cannot indicate if a transient in-
fection can progress towards clinically signiﬁcant disease. Conse-
quently, biomarkers to risk-stratify HPV infection are required. In
particular, a biomarker strategy that could identify those lesions that
are unlikely to progress to cancer would reduce healthcare costs and
clinic attendance time and anxiety for patients.
p16/Ki67 are robust biomarkers of high grade disease and have
Fig. 3. Categories of ratios of MCM and E4 staining. Graph of relative MCM
and E4 levels versus percentage of cells in each cell population evaluated.
HiMCM,> 20% MCM positivity. LoMCM,<20%MCM positivity. HiE4, ≥5%
positivity. LoE4 < 5% positivity.
Fig. 4. Percentage LBC cells positive for the biomarkers MCM and E4 versus histopathological grade of disease. A. MCM2 positivity considering CIN2+
and<=CIN1. B. MCM2 positivity considering CIN2+, CIN1/HPV+ve and normal/nil/no biopsy taken. C. E4 positivity considering CIN2+ and<=CIN1. D. E4
positivity considering CIN2+, CIN1/HPV+ve and normal/nil/no biopsy taken. The dots above the boxes on the plots are outlier values. p-values are shown above
the boxes on the plots.
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been assessed as a triage of primary HPV positivity in primary screening
[18–20]. Like p16 and Ki67, cellular MCM levels respond to increased
expression of viral oncoproteins E6 and E7 that mark clinically sig-
niﬁcant disease [12]. This is due to the central role of MCM2 in DNA
replication licensing [21], a process that is activated aberrantly by HPV
E6/E7 expression [22,23] [24]. A commercial assay is currently avail-
able to detect this protein, together with another DNA replication
marker TOP2A, in blocks of formalin-ﬁxed cervical lavage cells [11].
Conversely, HPV E4 marks clinically insigniﬁcant disease [12,13]. This
is because HPV E4 protein is expressed during the late stage of pro-
ductive HPV infections [10], which are not present, or present only at a
very low level, in CIN2+ [12]. In CIN2+, (except for E6 and E7 pro-
teins, whose expression is increased) expression of all viral proteins is
disrupted [2,3,6]. Therefore, E4 should be detected in HPV-positive
CIN1 or less. This hypothesis has been proved by analysis of tissue
sections representing diﬀerent grades of cervical disease [12]. Previous
studies indicated that these complementary biomarkers of cervical
disease could have prognostic capabilities [12]. Staining of formalin-
ﬁxed paraﬃn-embedded CIN1 lesions showed that the majority of cells
in the tissues stained positive for either E4 or MCM and only a few cells
showed dual staining. In CIN2+ high levels of MCM staining were
detected but E4 was rarely detected. Analysis of tissue sections can
reveal the pattern of biomarker expression and allow some quantiﬁ-
cation of levels of expression. However, it is diﬃcult to adapt for high
throughput settings such as screening.
LBCs are a suitable biospecimen for high-throughput contexts.
However, cell numbers in individual samples can vary widely and the
sample can contain HPV-infected and uninfected cells. Moreover, the
cells in the sample can represent a range of disease stages if these are
present across an individual cervix. Consequently, percentage positivity
for either biomarker assessed in the present study likely gives only an
estimate of their levels in-situ. Our choice of cut-oﬀ values for MCM and
E4 could be inappropriate given the small number of samples tested. It
will be useful in a future study with greater numbers of samples to
compare data with and without cut-oﬀ values. Despite these caveats, as
predicted by the previous tissue-based study, high MCM detection was
associated with CIN2+ and E4 association with<=CIN1 was close to
signiﬁcance. E4 expression levels can be very variable in CIN1 lesions
[12] and, as a cytoplasmic protein it may be more likely than a nuclear
protein to leach out of LBC cells during storage and processing. How-
ever, the low numbers of samples in the study will impact the sig-
niﬁcance of the E4 results. Some E4 was detected in histopathologi-
cally-deﬁned “normal” samples. These were HR-HPV positive and
therefore likely represent transient infections. A further study using a
larger cohort is required to validate E4 as a biomarker of clinically
insigniﬁcant disease in LBC samples, or conversely, that low or no E4
expression is a biomarker of CIN2+ . A previous study found that de-
tection of p16 but no detection of viral L1 protein was suﬃcient to
predict CIN3 [25]. It would be useful to investigate a quadruple bio-
marker matrix incorporating p16, MCM, E4 and L1 in an LBC-based
cervical disease risk-stratiﬁcation test. However, biomarker analysis is
not straightforward. For example, although p16 and MCM are bio-
markers of clinically signiﬁcant disease, the former is found in CIN1 and
CIN2+, albeit with a diﬀerent distribution, and is present in senescent
cells while the latter can be present during metaplasia or inﬂammation.
Detection of the viral biomarkers E4 and L1 seems to more restricted
to≤ CIN1 [12,13]. Thus combinations of markers, especially when
particular patterns are pathognomonic of disease, should oﬀer clear
beneﬁts.
In the developed world, a matrix test could be used as an adjunct to
HPV DNA testing to determine HPV activity in a lesion and predict the
probability of disease progression in primary screening, low-grade
triage or test of cure contexts. Approximately 70% of women who are
HR-HPV positive at primary screen are cytology negative and this group
represents a management challenge. A biomarker approach (either
stand-alone or adjunctive to cytology) which could mitigate against the
subjectivity of cytological observation and allow separation of low-
grade disease from signiﬁcant CIN would prove useful. In future,
chromogenic in situ HPV DNA staining could indicate how many LBC
cells in a sample are infected so MCM or E4 positivity could be calcu-
lated on HPV-positive cells only. Excellent antibodies against MCM are
commercially available. The pan-E4 antibody is available from DDL
Diagnostics Laboratory, The Netherlands [14]. It would also be im-
portant to know whether LBC samples from diﬀerent sources stain with
the selected antibodies to determine if transport or storage aﬀect the
protocol. Such technical optimisation, within the context of a wider
prospective study where MCM and E4 are considered as stand-alone
markers and as an adjunct to cytology, will be of value. Further as-
sessment of the technical and clinical performance of the E4/MCM test
would be required in longitudinal ﬁeld studies. It will be important in
future to compare this test with alternative strategies such as OncoE6
[26], which risk stratiﬁes high grade disease, or cytoactivL1 that risk
stratiﬁes low grade disease [27].
6. Conclusion
In this “proof of principle” study we have shown that MCM and E4
are a promising biomarker matrix for the separation of disease grade in
routinely taken cervical samples. MCM can identify CIN2+ when used
in the cytospin technique. Although E4 was detected in LBC cells, its
usefulness as a biomarker of clinically insigniﬁcant disease requires
further investigation in a larger LBC cohort. The cytospin approach
could prove useful in low and middle income settings lacking infra-
structure for standardised cytology and high-throughput HPV testing.
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